DBTECH

Dear Reader, As per your request, you have been removed from our mailing list for ET Learners Club Get all the updates from the world of business straight to your inbox Getting bigger and stronger. 4 million+ subscribers MANAGE ALL NEWSLETTERS » Daily Newsletter

VIEW IN BROWSER | SUBSCRIBE TUE, NOV 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Happy Tuesday! Analysts say Eli Lilly may have a future blockbuster drug on its hands: An experimental pill designed to lower an inherited form of high cholesterol.  The pharmaceutical giant presented mid-stage trial data on the pill , muvalaplin, at the American Heart Association meeting in Chicago on Monday. The treatment demonstrates the diversity of Eli Lilly's drug pipeline beyond its top-selling weight loss and diabetes treatments.  Here's what makes the daily pill so important: Muvalaplin is the only oral treatment among several injectable therapies being developed to treat high levels of lipoprotein(a) – or Lp(a) – in the blood, an inherited risk factor for heart disease. That includes Eli Lilly's own late-stage injectable drug, lepodisiran , and injections from Novartis and Amgen.  Abo